Related Experiment Video
Updated: Jan 22, 2026
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting
S Levolger1, E A C Wiemer2, J L A van Vugt1
1Department of Surgery, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.
Abstract:
Cancer mediated activation of the ActRIIB-ALK4/5 heterodimer by myostatin is strongly associated with muscle wasting. We investigated in vitro and in vivo the efficacy of ALK4/5 receptor blockers SB431542 and GW788388 in preventing muscle wasting, and explored synergy with IGF-I analogue LONG R3 (LR3) IGF-I. In vitro, C2C12 skeletal muscle cells were treated with vehicle, SB431542, GW788388 and LR3 IGF-I. A C26-CD2F1 cachexia model was used to induce cachexia in vivo. Mice were allocated as non-tumour bearing (NTB) or C26 tumour-bearing (C26 TB) vehicle control, treated with SB431542, LR3 IGF-I, SB431542 and LR3 IGF-I, or GW788388 (intraperitoneally or orally). In vitro, differentiation index and mean nuclei count increased using SB431542, GW788388, LR3 IGF-I. In vivo, GW788388 was superior to SB431542 in limiting loss of bodyweight, grip-strength and gastrocnemius weight. and downregulated Atrogin-1 expression comparable to NTB mice. LR3 IGF-I treatment limited loss of muscle mass, but at the expense of accelerated tumour growth. In conclusion, treatment with GW788388 prevented cancer cachexia, and downregulated associated ubiquitin ligase Atrogin-1.
Insights
The drug GW788388 effectively prevents cancer-induced muscle wasting by blocking ActRIIB-ALK4/5 signaling and reducing Atrogin-1. This approach offers a promising strategy against cancer cachexia.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Myostatin binding to the ActRIIB-ALK4/5 receptor complex drives muscle wasting in cancer.
- Cancer cachexia leads to significant loss of muscle mass and function.
Purpose of the Study:
- To evaluate ALK4/5 receptor blockers (SB431542, GW788388) for preventing cancer-induced muscle wasting.
- To explore potential synergy between ALK4/5 blockers and IGF-I analogue (LR3 IGF-I).
Main Methods:
- In vitro studies used C2C12 skeletal muscle cells treated with blockers and LR3 IGF-I.
- In vivo studies utilized a C26-CD2F1 mouse model of cancer cachexia.
- Mice received treatments including SB431542, GW788388, and LR3 IGF-I via intraperitoneal or oral administration.
Main Results:
- In vitro, SB431542, GW788388, and LR3 IGF-I enhanced muscle cell differentiation and nuclei count.
- In vivo, GW788388 outperformed SB431542 in preserving body weight, grip strength, and gastrocnemius muscle weight.
- GW788388 treatment normalized Atrogin-1 expression, while LR3 IGF-I accelerated tumor growth despite limiting muscle loss.
Conclusions:
- GW788388 effectively prevents cancer cachexia and reduces muscle-specific ubiquitin ligase Atrogin-1 expression.
- While LR3 IGF-I mitigates muscle loss, it promotes tumor progression, highlighting the importance of targeted cachexia therapies.
More Related Videos
Related Concept Videos
02:42Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
02:54Protein Kinases and Phosphatases
00:46Feedback Inhibition
01:045-Number Summary
In a box plot, the minimum and maximum data values represent the lower and upper whiskers in the graph, and the median is designated as the center of the box in the chart. The first quartile and third...
01:26Receptor Tyrosine Kinases